Statins After 70: Fewer Heart Attacks, But No Extra Healthy Years

Stocks barely moved. The 10-year yield hit a 24-year high. Consumer confidence hit a 12-year low.

The quick scan: A quiet close hid a loud backdrop. All three indices slipped modestly on Tuesday, but the numbers underneath were anything but calm. The 10-year Treasury yield touched its highest level since 2002, and the 30-year pushed above 5.6%. The Conference Board's consumer confidence index dropped 6.7 points to 81.9, its lowest in more than 12 years, when economists had expected a rise. Job openings slipped to 7.08 million. Oil eased, and a late comment from the New York Fed helped stocks pare their losses.

S&P 500: -0.17% to 7,670.84 – drifted in a tight range as most stocks fell and a handful of tech giants cushioned the index; down 0.9% for the week so far
Dow Jones: -0.26% to 51,349.92 – fell 131.59 points for a second straight loss; financials, down more than 6% in September, remain one of the month's biggest drags
NASDAQ: -0.09% to 26,797.54 – the most resilient of the three; chip and AI names gave back early gains as the session wore on

What's driving it: Bonds, not stocks, told the day's story. Oil-driven inflation fears have pushed long-term yields to levels not seen in more than two decades, and higher yields make borrowing dearer for households and companies alike. The Fed raised rates recently, and futures markets put roughly a 68% chance on another hike in October, according to CME FedWatch. New York Fed President John Williams suggested the central bank could wait until December, which helped stocks claw back some ground late in the day. Consumers are clearly feeling the squeeze: Americans told the Conference Board that jobs feel scarcer and they are pulling back on plans for homes, cars and big-ticket purchases. Oil offered some relief, with Brent crude down 1.7% to $96.16 as mediators keep working on a US-Iran deal. Wednesday brings the August PCE inflation reading, the Fed's preferred gauge, expected at 3.7%.

Bottom line: A 0.17% dip sounds like nothing, and on its own it is. The bigger number is a 10-year yield at a 24-year high, which quietly reprices everything from mortgages to bond funds. Today's article makes a similar point about health headlines: the percentage that grabs attention is not always the figure that matters most. For L-Plate Retirees, the index move is noise. Rising yields are the signal to watch, especially for anyone holding longer-dated bonds or planning to borrow.

A Statin After 70 Cut Heart Attacks by 30%. So Why Didn't It Add Healthy Years?

The scoop: Picture yourself at 74. Your knees grumble on the stairs, but your heart has never given you a day's trouble. No diabetes, no memory worries, no history of heart attack or stroke. Then your doctor mentions a cholesterol-lowering pill, taken once a day, possibly for life. Would you take it?

For years the fair answer has been a shrug. Statins have a long track record in people who already have heart disease, and in middle-aged people at risk. But healthy older adults were thin on the ground in the big trials that built that record. The guidance shows it: in the US, both the ACC/AHA and the US Preventive Services Task Force are equivocal about starting a statin after 75.

Now there is a direct answer, or at least a much better one. A large Australian trial called STAREE, presented at the European Society of Cardiology Congress in late August and published simultaneously in the New England Journal of Medicine, tested exactly this group. It came back with two results, not one. You need both.

Who was in the trial

STAREE recruited 9,971 adults aged 70 and over through Australian general practice. None had a history of clinical cardiovascular disease, diabetes or dementia. Their average age was 74.7, and 52% were women.

Half were randomly assigned to atorvastatin 40 mg a day. The other half took an identical-looking placebo. Neither the participants nor the researchers assessing them knew who was taking which. That double-blind design means differences between the groups can be put down to the drug, not to the kind of people who choose it.

Participants were followed for a median of 5.9 years. According to the European Society of Cardiology, it is the first large randomised trial of statins for primary prevention (preventing a first event, rather than a repeat) specifically in older adults.

Result one: fewer heart attacks and strokes

The first main measure was major cardiovascular events: death from heart disease, a nonfatal heart attack, a stroke, or a procedure to reopen blocked heart arteries.

On the statin, 6.0% of people had one of these events. On placebo, 8.3% did. That is a 30% relative reduction, the headline you may have seen.

Relative numbers flatter, though. In absolute terms the gap was 2.3 percentage points over roughly six years: out of every 100 people like those in the trial, a little over eight on placebo had a major event, against six on the statin. A real benefit, and a smaller-sounding one than "30%".

The hazard ratio was 0.70 (95% confidence interval 0.61 to 0.82), a range comfortably below 1.

Result two: no extra healthy years

The second main measure tends to fall out of the headlines. The researchers also tracked disability-free survival: staying alive without dementia and without persistent physical disability.

Here the statin made no meaningful difference. Death, dementia or persistent disability occurred in 12.8% of the statin group and 13.6% of the placebo group. The hazard ratio was 0.94, with a confidence interval of 0.84 to 1.05. Because that range crosses 1, the result is not statistically significant. The small gap could simply be chance.

For many of us past 70, that second measure is the one that matters most. Plenty of people are less afraid of dying than of the slow losses before it: the car keys, the stairs, the thread of a conversation. A 30% cut in heart events is not the same thing as more good years, and this trial did not show more good years.

What about side effects?

Muscle, liver and diabetes-related adverse events were more frequent in the statin group. Serious adverse events were identical in both groups at 2.7%.

Reassuring, with a caveat: "more frequent" still means some people on the statin had problems they would not otherwise have had. Whether that trade is worth it is a conversation for your own doctor.

Who this does and does not apply to

The trial deliberately excluded people with diabetes, dementia or known heart disease. If you have any of those, these results do not describe you. Please do not start, stop or change any medication on the strength of a newsletter.

It is also an Australian trial. Guidelines in the US, Singapore, Malaysia and elsewhere are set by their own bodies, and this trial does not tell us what any of them will do.

The research was funded by Australia's National Health and Medical Research Council and the Heart Foundation, and atorvastatin is a generic drug. The lead author, Professor Sophia Zoungas of Monash University, discloses institutional consultancy payments from several drugmakers for unrelated work.

What happens next

Zoungas estimates that around 21,000 older Australians have a major cardiovascular event every year, and says she hopes to see updated guidelines.

Meanwhile, a US trial called PREVENTABLE, enrolling up to 20,000 adults aged 75 and over, is still running. Until then, STAREE is one large, well-run trial, and one trial is a strong signal rather than the last word.

Two results, one decision

STAREE refuses to give a tidy answer. It hands older adults two facts – fewer heart events, no extra disability-free years – and asks them to hold both at once.

That makes the decision personal. Someone most afraid of a heart attack or stroke may read this trial one way; someone focused on staying independent and clear-headed, another. Both deserve a doctor who will walk through the full numbers with them, not a headline that hands them half the story.

Actionable takeaways for L-Plate Retirees:

• Ask for absolute numbers, not just percentages. A "30% reduction" sounds dramatic. In STAREE it meant major heart events in 6.0% of people on the statin versus 8.3% on placebo over roughly six years. When any treatment is described to you in relative terms, ask what the before-and-after numbers look like for someone like you.

• Look for the second result in every health headline. STAREE had two main measures, and only one of them was positive. When a study makes the news, check whether the headline reports everything the researchers measured or only the part that worked.

• Know which group a study actually tested. This trial included Australians aged 70 and over with no diabetes, dementia or known heart disease. If that is not you, the findings do not transfer neatly. Bring your own history to the conversation rather than borrowing someone else's result.

• Take the question to your doctor, not your medicine cabinet. Nothing here is a reason to start, stop or change a medication yourself. If you are over 70 and have never discussed a statin, or you already take one and wonder whether it still fits, book the conversation.

• Decide what you are protecting. Some people rank avoiding a heart attack or stroke above everything. Others care most about staying independent and mentally sharp. STAREE suggests a statin helps with the first and, over about six years, not measurably with the second. Knowing your priority sharpens that conversation.

• Treat one trial as a strong signal, not the final word. STAREE is large, randomised and double-blind, which makes it the best evidence yet for this age group. The US PREVENTABLE trial, with up to 20,000 adults aged 75 and over, is still running.

Your Turn: 
If your doctor offered you a daily pill that cut your risk of a heart attack or stroke by 30% but did not add healthy, independent years, would you take it – and what would tip the decision? 
When you read a health headline, do you look for the absolute numbers behind the percentage, or does the percentage do the persuading? 
Which matters more to you over the next decade – avoiding a major heart event, or staying independent and mentally sharp – and has anyone ever asked you that question directly?

👉 Hit reply and share your thoughts – your answers could inspire fellow readers in future issues.

If this issue helped you see that lowering blood pressure might begin with the greens on your plate and the bacteria in your mouth, consider shouting L-Plate Retiree a coffee on Ko-fi. Your support keeps us reading the actual journal paper instead of settling for whichever headline travelled the furthest.